Takeda Announces the Appointment of New Senior Leadership and Organizational Change

Takeda Announces the Appointment of New Senior Leadership and Organizational Change

Osaka, Japan, June 24, 2013 --- Takeda Pharmaceutical Company Limited today announced the appointment of new senior leadership as well as the establishment of a new organization, realignment of current organizations, and change of organization names effective July 1st, 2013.
Details are as follows:

1. New senior leadership effective July 1, 2013;
New assignment Previous assignment Name
Pharmaceutical Production Division (PPD)
Vice President,
Strategic Production Department
(Director,
Strategic Production Planning, Product Planning & Administration Department, PPD)
Koichi Kamiyama
Director,
IT Planning & Administration Office
(Director,
IT Planning & Administration,
Product Planning & Administration Department, PPD)
Takashi Itano
Director,
HR Development Office
(Director,
HR Development,
Product Planning & Administration Department, PPD)
Miho Fujisawa
Vice President,
Osaka Plant
(Vice President,
Hikari Plant, PPD)
Masakazu Matsui
Senior Director,
Pharmaceutical Manufacturing Department, Osaka Plant
(Associate Director,
PPD, Takeda Ireland)
Keiichi Yamamoto
Vice President,
Hikari Plant
(Vice President,
Product Planning & Administration Department, PPD)
Toru Ishida
Global Marketing Division Tokyo
Head of Global Marketing Division
Tokyo - appointed concurrently with the "Previous assignment"
(Head of Global Marketing,
Takeda Pharmaceuticals International GmbH)
Michael Williams
2. Organizational changes effective July 1, 2013;
  • Pharmaceutical Production Division
    • Change of organization name;
      • - "Product Planning & Administration Department" to "Strategic Production Department"
    • Establishment of new organization;
      • - IT Planning & Administration Office
      • - HR Development Office
    • Ÿ Realignment of current organization;
      • - "Overseas Project Management Department" to be dissolved, and its current job responsibility is transferred to "Strategic Production Department"
  • Establishment of "Global Marketing Division Tokyo*"
  • *"Global Customer Market Business Insights Department" will belong to this division.

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.